Condition: Vorolanib · Clear Cell Renal Cell Carcinoma (ccRCC) · Neoadjuvant Therapy · Sponsor: Sun Yat-sen University
Through the neoadjuvant treatment with a combination of Pucotenlimab and Vorolanib, it enabled the successful and safe implementation of partial nephrectomy in patients with localized renal cancer, who had indications for nephron-sparing surgery but faced considerable difficulty in preserving the kidney (T1b with an endophytic component ≥75% or T2)
This description comes directly from the study's public registry record.
Zhiling Zhang, M.D · +862087342318 · zhangzhl@sysucc.org.cn
Yulu Peng, M.D · +862087342318 · pengyl1@sysucc.org.cn
Always discuss trial participation with your own doctor first.
| Sun Yat-sen University Cancer Center | Guangzhou, Other (Non U.s.), China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07386158